TEZSPIRE trial shows EoE improvements at week 52

• AstraZeneca and Amgen reported Phase III CROSSING trial results showing TEZSPIRE improved eosinophilic esophagitis outcomes through week 52.
• The trial met all co-primary and key secondary endpoints at week 24 compared with placebo.
• The companies said the results support further evaluation of TEZSPIRE in another epithelial-driven inflammatory disease.

AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN) reported Phase III CROSSING trial results showing TEZSPIRE® (tezepelumab-ekko) achieved statistically significant improvements in eosinophilic esophagitis outcomes, with benefits maintained through week 52.

The randomized, double-blind trial evaluated TEZSPIRE administered every four weeks compared with placebo in adults and adolescents with symptomatic and uncontrolled eosinophilic esophagitis, with results showing improvements across co-primary and key secondary endpoints.

The CROSSING trial evaluated histologic remission and changes in dysphagia symptoms measured through the Dysphagia Symptom Questionnaire, while the companies stated that the safety profile of TEZSPIRE remained consistent with approved indications.

The companies stated that full trial results will be shared with regulatory authorities and the scientific community at an upcoming medical meeting.

Eosinophilic esophagitis is a chronic inflammatory disorder affecting the esophagus, with more than 470,000 people affected in the United States, according to the companies, and current treatments include dietary restrictions, swallowed corticosteroids, and proton pump inhibitors.

TEZSPIRE is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in inflammatory pathways, and is currently approved for severe asthma and chronic rhinosinusitis with nasal polyps in several markets.